Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Blood (2025) 146 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2025-4069

Published: 2025

Journal Articles

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4042.

https://doi.org/10.1182/blood-2025-4042

Published: 2025

Journal Articles

Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

Amanda Duplan, Conn Mallett, Yead Jewel, Miso Park, Preeti Sharma, Asaul Gonzalez, Kevin Ly, Hyeran Choi, Bea Parcutela, Carmina Ladra, Amrita Krishnan, Flavia Pichiorri, John Williams

Blood (2025) 146 (Supplement 1): 2161.

https://doi.org/10.1182/blood-2025-2161

Published: 2025

Journal Articles

Immune population dynamics predict multiple myeloma progression while on daratumumab maintenance therapy following autologous stem cell transplant

Ryan Woodall, Alexander Pozhitkov, Azra Borogovac, Theophilus Tandoh, Alexander Brummer, Vikram Adhikarla, James Sanchez, Hearn Cho, Jeffrey Matous, Jesús Berdeja, Amrita Krishnan, Russell Rockne, Flavia Pichiorri

Blood (2025) 146 (Supplement 1): 7451.

https://doi.org/10.1182/blood-2025-7451

Published: 2025

Journal Articles

Safety and efficacy of out-of-specification ciltacabtagene autoleucel (cilta-cel) in Relapsed/Refractory multiple myeloma (RRMM)

Azra Borogovac, Murali Janakiram, NI-Chun Tsai, Ann Morales, James Sanchez, Sarah Lee, Scott Goldsmith, Nitya Nathwani, Firoozeh Sahebi, Michael Rosenzweig, Amrita Krishnan, Myo Htut

Blood (2025) 146 (Supplement 1): 405.

https://doi.org/10.1182/blood-2025-405

Published: 2025

Journal Articles

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2025-4598

Published: 2025

Journal Articles

Anti-CD38 targeted radiation is effective and enhances CAR-T cell recruitment and expansion in resistant extramedullary multiple myeloma

Enrico Caserta, Vikram Adhikarla, Maxim Kuznetkov, Ruby Espinosa, Mariam Murtadha, James Sanchez, Scott Goldsmith, Amrita Krishnan, Russell Rockne, John Shively, Xiuli Wang, Flavia Pichiorri

Blood (2025) 146 (Supplement 1): 801.

https://doi.org/10.1182/blood-2025-801

Published: 2025

Journal Articles

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 137.

https://doi.org/10.1182/blood-2025-137

Published: 2025

Journal Articles

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Blood (2025) 146 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2025-6364

Published: 2025

Journal Articles

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

Blood (2024) 143 (16): 1599–1615.

https://doi.org/10.1182/blood.2023021570

Published: 2024

Includes: Supplemental data

Journal Articles

Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3296.

https://doi.org/10.1182/blood-2023-190157

Published: 2023

Journal Articles

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Ajai Chari, Albert Oriol, Amrita Krishnan, Maria Del Carmen Martinez Chamorro, Luciano Costa, Maria Victoria Mateos, Monique C Minnema, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, M. Damiette Smit, Swarna Ramanjulu, Paula Rodríguez Otero

Blood (2023) 142 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2023-181228

Published: 2023

Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Blood (2023) 142 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2023-182330

Published: 2023

Journal Articles

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Blood (2023) 142 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2023-184710

Published: 2023

Journal Articles

Impact of Health Insurance and Access to Autologous Stem Cell Transplantation (ASCT) on Racial Inequity in Overall Survival (OS) Among Patients with Multiple Myeloma (MM)

F. Lennie Wong, Scott R. Goldsmith, Kimlin Ashing, Amrita Krishnan, Michael Rosenzweig, Saro Armenian

Blood (2023) 142 (Supplement 1): 4730.

https://doi.org/10.1182/blood-2023-174296

Published: 2023

Journal Articles

CD38-Directed, Single-Chain T Cell-Engager Targets Leukemia Stem Cells through IFNγ-Induced CD38 Expression

Blood (2023) 142 (Supplement 1): 2797.

https://doi.org/10.1182/blood-2023-189901

Published: 2023

Journal Articles

Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia

Robert Allen Vescio, Yuliya Linhares, Ryan Ponec, Christopher Lopiccolo, Amanda Park, Rhona Castillo, Amrita Krishnan

Blood (2023) 142 (Supplement 1): 7057.

https://doi.org/10.1182/blood-2023-181957

Published: 2023

Journal Articles

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Lawrence Liu, Scott R. Goldsmith, Sheryl Leahey, Carlos Gomez Luna, Shawn Streeter, Adam Braun, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, Azra Borogovac, Jonathan Keats, Myo Htut, Arnab Chowdhury, Sanjeet Singh Dadwal, Amrita Krishnan, Murali Janakiram

Blood (2023) 142 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2023-188077

Published: 2023

Journal Articles

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Jesus G. Berdeja, MD, Albert Oriol, Niels W. C. J. van de Donk, MD, Paula Rodriguez, Elham Askari, Maria-Victoria Mateos, MD PhD, Monique C. Minnema, MD PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Thomas Prior, Brandi W. Hilder, PhD, Jeffery Russell, MD PhD, Jenna D. Goldberg, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-133873

Published: 2020

Journal Articles

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Amrita Krishnan, MD, Rafael Fonseca, MD, Peter A Forsberg, MD, Andrew Spencer, Jesus G. Berdeja, MD, Jacob P. Laubach, MD, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M Fine, Suzanne Trudel

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136985

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

Immune population dynamics predict multiple myeloma progression while on daratumumab maintenance therapy following autologous stem cell transplant

Safety and efficacy of out-of-specification ciltacabtagene autoleucel (cilta-cel) in Relapsed/Refractory multiple myeloma (RRMM)

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Anti-CD38 targeted radiation is effective and enhances CAR-T cell recruitment and expansion in resistant extramedullary multiple myeloma

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Impact of Health Insurance and Access to Autologous Stem Cell Transplantation (ASCT) on Racial Inequity in Overall Survival (OS) Among Patients with Multiple Myeloma (MM)

CD38-Directed, Single-Chain T Cell-Engager Targets Leukemia Stem Cells through IFNγ-Induced CD38 Expression

Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only